MSSU summer academy ignites STEM career interest
This is year two for the Middle School Science to Jobs Summer Academy at MSSU.The camps, which is open to current 5th through 7th grade students in Missouri, gives kids a chance to explore the natural world, perform experiments and learn about jobs in the sciences.
Weather delays opening of Joplin's West 20th Street intersection
MSSU summer academy ignites STEM career interest
It's not your mamma's driver's ed course
Alzheimer's Awareness Month: Caregiver tips to avoid financial scams
The 20 closest national parks to Joplin
The goal is to inspire a passion for the sciences lasting the rest of their lives.
'I think my favorite part of science and jobs Academy is the excitement of the students getting to experience all of just the science exploration components. So they're getting exposure to like forensic science and health science and environmental science. They get to experience um activities where they've kind of going beyond the textbook and they get to take activities and apply them into real world scenarios,' said Debra Kwolek, 'Science to Jobs' Summer Academy Co-director.
Roughly 160 students from across the state are in town for the two-day camp. Last week, Missouri Southern hosted a similar academy geared towards high school students.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine
ST. PAUL, Minn., Aug. 5, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sidra Medicine, a women and children's hospital in Qatar, has been awarded a $100,000 G-Rex® Grant. Sidra Medicine's G-Rex® Grant will enable expeditious development, validation, and implementation of a G-Rex® centric CAR-T cell production platform. The G-Rex Grant will allow Sidra Medicine to perform the processes and preclinical development for a CD19 CAR-T cell therapy product that will initially be used in pediatric oncology settings. Sidra Medicine will also receive early access to the G-CART™ process currently in development at Cell Ready, the world's first and only G-Rex centric contract development and manufacturing organization (CDMO). The Grant will also support the implementation of fully closed system, semi-automated G-Rex production compliant with current Good Manufacturing Practices (cGMPs). Lastly, the Grant will support the technology transfer to Sidra Medicine's newly established GMP facility for qualification and implementation. "Sidra Medicine is a pioneering healthcare institution that has innovation weaved into the very core of its precision medicine program. Our GMP facility has been specifically set up to develop better treatment protocols for pediatric diseases including cancers, genetic and rare diseases. The G-Rex® Grant will play a key role in accelerating the readiness of our protocols, particularly for Sidra Medicine's pediatric oncology program. Our preliminary findings have already shown us that the G-Rex® method is outstanding in its simplicity and the unique T cell phenotype resulting from the cell culture. This methodology will allow us to implement an affordable, highly efficient G-Rex based cell manufacturing platform with the most suitable T cell phenotype, ultimately having a positive impact on pediatric patient care and cure," said Sara Deola, M.D., Ph.D., Research Investigator at Sidra Medicine. "We're eager to support the emerging Cell & Gene Therapy (CGT) industry in Qatar and the Middle East. By entering the field of CAR-T without any preconceived manufacturing notions and quickly gathering and reviewing G-Rex manufacturing data, Sidra Medicine quickly recognized the full array of advantages that our G-Rex centric manufacturing process offers relative to alternatives. Sidra Medicine's quick grasp of the technical and economic advantages of G-Rex relative to alternatives gives us confidence that this grant will set the stage for low cost and fully scalable CAR-T manufacturing in Qatar and the Middle East." said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. ScaleReady's G-Rex Grant Program has now surpassed $40M of no-cost product commitments to grant recipients with the goal of advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing. Individual Grant Awards are worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program ScaleReady has partnered with Hanson Wade to launch an event series called LEAN Cell & Gene™. All CGT entities are invited to attend and will learn how to systematically identify and eliminate waste, stabilize business operations, increase drug product quality and supply, and develop a LEAN approach to cell and gene therapy development and manufacturing. For more information about the G-Rex® Grant Program, please contact info@ For more information about LEAN Cell & Gene™, please use this link to register for the free event series. About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Sidra Medicine Innovating Care. Transforming Lives From the heart of Qatar, Sidra Medicine, is a private, not-for-profit academic healthcare and research institution for women, children, and young people. Established by the Qatar Foundation for Education, Science, and Community Development, Sidra Medicine is committed to delivering exceptional patient and family-focused care, conducting innovative biomedical and clinical research, and providing a personalized journey of care and cure and precision medicine specifically for rare and genetic diseases. To access our specialised healthcare or international patient services, including pediatric care, women's health, and rare disease treatment or to book a consultation at one of our private clinics, please call +974 40033333 or visit our website at For more information, follow us on Facebook, Instagram, X and LinkedIn. View original content to download multimedia: SOURCE Bio-Techne Corporation
Medscape
30-07-2025
- Medscape
‘Clinical Obesity' Definition Shifts Obesity Prevalence
The adoption of the new 'clinical obesity' definition alters prevalence estimates of obesity in many parts of the world compared with BMI-based definitions, new data suggested. In January 2025, a Lancet Commission proposed that the diagnosis of obesity first be made via confirmation of excess adiposity using measures such as waist circumference or waist-to-hip ratio in addition to BMI. Next, a clinical assessment of signs and symptoms of organ dysfunction due to obesity and/or functional limitations determines whether the individual has the disease 'clinical obesity' or 'preclinical obesity,' a condition of health risk but not an illness itself. That definition, although endorsed by more than 75 professional medical organizations, has proved controversial, with a commonly cited concern that people in the 'preclinical obesity' category might be denied needed care. But the Lancet authors counter that the 'preclinical' obesity category should be treated as a health risk factor, no differently than hypertension or dyslipidemia. A new analysis of nationally representative surveys from 56 mostly low- and middle-income countries (LMICs) showed that application of a modified version of the 'clinical obesity' definition would reduce obesity prevalence by more than 50% in some regions. It was published on July 24, 2025, in PLOS Global Public Health . 'Our results emphasize the need to carefully consider how obesity is defined in population surveillance to ensure its relevance to health outcomes. While the clinical obesity framework offers a more precise measure of obesity-related disease burden, its implementation in routine surveillance will require further adaptation to overcome data availability challenges,' the authors wrote. Lead author Rodrigo M. Carrillo-Larco, MD, PhD, of the Department of Global Health at Emory University, Atlanta, told Medscape Medical News that there is a need for 'agreement on whether the definition has to change and for what purposes so that the right tools and specific definitions are in place. If for clinical purposes, what definition should be used to start pharmacologic treatment, for claims and reimbursement, and for risk stratification of other diseases?' In the paper, Carrillo-Larco and colleagues express the concern that with the new definition, 'there is little to no opportunity for primary prevention of clinical obesity, as its definition already includes a cardiometabolic condition that most likely warrants secondary prevention or treatment.' However, Lancet Commission Chair Francesco Rubino, MD, professor and chair of metabolic and bariatric surgery at King's College London, London, England, told Medscape Medical News that this perception is incorrect. 'Clinical obesity represents only a subset of the broader obesity spectrum. Total obesity prevalence should include both clinical and preclinical obesity.' Added Lancet Commission member Ricardo Cohen, MD, director of the Center for Obesity and Diabetes, Oswaldo Cruz German Hospital, São Paulo, Brazil, 'The published paper demonstrates that prevalence estimates shift because the clinical definition targets those with higher medical need and not because fewer people require care. This is about better risk stratification, not exclusion.' Clinical Obesity Prevalence Differs From BMI-Only Obesity The study included nationally representative data from the World Health Organization's STEPS Survey for a total of 142,250 people in 56 countries in six world regions, including Africa (n = 49,438 from 18 countries), the Americas ( n = 3083 from one country), the Eastern Mediterranean (n = 19,292 from nine countries), Europe (n = 17,536 from seven countries), Southeast Asia (n = 27,334 from six countries), and the Western Pacific ( n = 25,567 from 15 countries). Carrillo-Larco told Medscape Medical News that LMICs were sampled because 'obesity may impose a greater burden in LMICs, given the limitations in access to treatment and counseling for obesity as well as for related comorbidities.' The clinical obesity definition used for the study included objective measures of weight, height, waist circumference, blood pressure, fasting plasma glucose, and total cholesterol. The Lancet definition includes a longer list of conditions, but the authors note that those data are not routinely available in many LMICs. Rubino said this could lead to an underestimate of the true prevalence of obesity. On the other hand, Carrillo-Larco and colleagues noted that the lack of such data in many countries represents a limitation of the definition. At the national level, the prevalence of clinical obesity in men ranged from less than 1% in Timor-Leste, Rwanda, Malawi, Ethiopia, Eritrea, and Cambodia to 29% in American Samoa, the Cook Islands, and Tokelau. In women, clinical obesity prevalence was as low as ≤ 1% in Vietnam, Timor-Leste, Rwanda, Ethiopia, Eritrea, and Cambodia, and as high as 28% in American Samoa and Tuvalu. Among men, the age-standardized prevalence of clinical obesity was < 10% in 41 countries, mostly in Africa (18/41). Among women, the age-standardized prevalence of clinical obesity was less than 10% in 30 countries, also mostly in Africa (14/30). The largest shift in prevalence occurred in Malawi, with BMI-only obesity in 0.7% vs clinical obesity in 0.2%, a relative reduction of 67.7%. However, the absolute change was less than 1 percentage point. Countries experiencing both a relative change of ≥ 10% and an absolute change of ≥ 10 percentage points were Nauru (-35.5% relative change and 13.3 percentage points in absolute change; prevalence of clinical obesity was 24.2% and that of BMI-only obesity was 37.5%) and Qatar (-49.2% and 10.3; prevalence of clinical obesity was 10.6% and that of BMI-only obesity was 20.9%). In women, the relative change in prevalence exceeded 50% in Malawi (relative reduction of 52.8%; 5.6% for BMI-only obesity and 2.6% for clinical obesity) and Rwanda (-52.4%; 2.7% for BMI-only obesity and 1.3% for clinical obesity). In Malawi and Rwanda, the absolute change was 2.9 and 1.4 percentage points, respectively. Countries with both relative and absolute changes exceeding 10% and 10 percentage points, respectively, were in the Western Pacific (American Samoa, Nauru, Niue, Samoa, Tokelau, and Tuvalu). Rubino told Medscape Medical News , 'Distinguishing clinical from preclinical obesity doesn't reduce urgency — it ensures timely treatment for those who need it and directs prevention toward those for whom it remains possible.' Regardless, Carrillo-Larco said, 'Clinicians should always consider obesity as a multifactorial condition for which nonpharmacologic conditions are very important and social determinants of health play a key role.' The authors received no specific funding. Rubino declared having received research grants from Ethicon (Johnson & Johnson), Novo Nordisk, and Medtronic; consulting fees from Morphic Medical; and speaking honoraria from Medtronic, Ethicon, Novo Nordisk, Eli Lilly, and Amgen. He has also served (unpaid) as a member of the scientific advisory board for Keyron and as a member of the data safety and monitoring board for GI Metabolic Solutions. Cohen declared having received research grants from Johnson & Johnson and Medtronic; honoraria for lectures and presentations from Johnson & Johnson, Medtronic, and Novo Nordisk; and serving on scientific advisory boards for Morphic Medical, Johnson & Johnson, and Medtronic.
Yahoo
09-06-2025
- Yahoo
MSSU summer academy ignites STEM career interest
JOPLIN, Mo. — A summer camp designed to spark an interest in math and science returns to Missouri Southern. This is year two for the Middle School Science to Jobs Summer Academy at camps, which is open to current 5th through 7th grade students in Missouri, gives kids a chance to explore the natural world, perform experiments and learn about jobs in the sciences. Weather delays opening of Joplin's West 20th Street intersection MSSU summer academy ignites STEM career interest It's not your mamma's driver's ed course Alzheimer's Awareness Month: Caregiver tips to avoid financial scams The 20 closest national parks to Joplin The goal is to inspire a passion for the sciences lasting the rest of their lives. 'I think my favorite part of science and jobs Academy is the excitement of the students getting to experience all of just the science exploration components. So they're getting exposure to like forensic science and health science and environmental science. They get to experience um activities where they've kind of going beyond the textbook and they get to take activities and apply them into real world scenarios,' said Debra Kwolek, 'Science to Jobs' Summer Academy Co-director. Roughly 160 students from across the state are in town for the two-day camp. Last week, Missouri Southern hosted a similar academy geared towards high school students. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
